iCAD ANNOUNCES POSTER PRESENTATION OF XOFT SYSTEM TO TREAT SKIN CANCER HIGHLIGHTED AT 2013 AMERICAN BRACHYTHERAPY SOCIETY ANNUAL MEETING

Positive Data Show Xoft a Good Alternative to Surgery for Non-Melanoma Skin Cancer with No Recurrences and Good Cosmetic Outcomes after One Year Follow Up

NEW ORLEANS – April 18, 2013 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that positive data in support of the Company’s Xoft® Axxent® Electronic Brachytherapy System® to treat non-melanoma skin cancer (NMSC) were highlighted in a poster presentation today at the 2013 American Brachytherapy Society (ABS) Annual Meeting being held from April 18-20, 2013 in New Orleans.

Ajay Bhatnagar, MD, MBA, Department of Radiation Oncology, School of Medicine at the University of Pittsburgh, and Co-Director of Cancer Treatment Services in Casa Grande, Ariz. presented clinical outcomes data on 172 patients with 247 NMSC lesions treated with high-dose-rate (HDR) electronic brachytherapy with surface applicators, using the Xoft System. Data on earlier follow-up on this patient cohort was published in the journal Brachytherapy in March/April 2013.

“HDR electronic brachytherapy is a convenient, non-surgical treatment option for non-melanoma skin cancer, especially for hard to reach lesions on the tip of the nose, eyelids and behind the ear. The data presented today demonstrate good cosmetic results, low toxicity and, most importantly, no recurrence at one year and more from treatment,” said Dr. Bhatnagar. “The Xoft System allows us to drastically reduce treatment time, making it an ideal option for elderly patients.”

“We are encouraged by the data presented on the Xoft System for non-melanoma skin cancer, as it further demonstrates the system’s effectiveness,” said Ken Ferry, President and CEO of iCAD. “Increased evidence of improved clinical outcomes combined with shorter treatment times and the system’s mobility are contributing to the rapid adoption of the Xoft System.”

About Non-Melanoma Skin Cancer
NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is not only the most common type of skin cancer, it is the most common type of cancer in humans. These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips, and backs of the hands. NMSC affects approximately 2.2 million Americans each year.

About Xoft® Axxent® Electronic Brachytherapy System®
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. A post-market study is underway to assess the safety and efficacy of Intraoperative Radiation Therapy with the Xoft System. Xoft, Inc. is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com.

About iCAD, Inc.
iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, cervical cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.

For iCAD, contact Kevin Burns at 937-431-7967 or via email at kburns@icadmed.com

For iCAD investor relations, contact Anne Marie Fields of LHA at 212-838-3777 x6604 or via email at afields@lhai.com

For iCAD media inquiries, contact Helen Shik of Schwartz MSL at 781-684-0770 or via email at iCAD@schwartzmsl.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

# # #